Eva Wesley

Sanofi will invest €1 billion in a new insulin factory in Beijing, its largest investment in China, citing demand from 140 million diabetic adults. This fourth plant aligns with sustainable standards. While Pfizer plans $1 billion in China by 2030, rivals like AstraZeneca, Johnson & Johnson, and Merck are scaling back operations.

Eli Lilly will invest $3 billion to expand its Kenosha, Wisconsin, facility, acquired for $100 million in April. The site will manufacture injectable diabetes and obesity drugs, employ 750 workers, and add 8,000 square meters. This marks Lilly’s largest U.S. investment outside Indiana, complementing a $4.5 billion expansion announced last October. 0 SHARES

Croma Gio.Batta Iberia, post-merger with Cogesa, anticipates double-digit growth fueled by a 15% revenue rise to over €30M. The group, now a leading provider of healthcare logistics and medical equipment, plans international expansion, AI projects, and acquisitions. Cogesa’s traceability system for prostheses and implants adds to its pioneering biomedical logistics expertise.

Quirónsalud and Roche Farma España have signed a partnership to advance healthcare innovation and clinical research, focusing on oncology, neurosciences, and ophthalmology. The agreement includes precision medicine projects, professional training, and fostering early patient access to innovation. With over 1,300 clinical trials underway, this collaboration aims to enhance health outcomes and drive medical progress. 0 SHARES

Bayer expands its Barcelona innovation hub with a new R&D area for health and agriculture, integrating 82 professionals to advance clinical trials and medicine safety. The hub, operational since 2001, now serves 11 countries. Bayer invested €5.8 billion globally in R&D last year, despite a 2.5% drop in sales and rising losses.

Ozempic, manufactured by Novo Nordisk, gains EMA approval for chronic kidney disease, reducing disease progression by 24%, per the Flow trial. With 40% of type 2 diabetes patients developing kidney issues, it’s the first GLP-1 receptor agonist for this use. Novo Nordisk’s Q3 revenue surged 48%, driven by Ozempic, Wegovy, and innovative therapies like CagriSema. 0 SHARES

Roche plans to use this new technology in patients receiving hormonal therapy such as those with breast cancer, for example.

Novo Nordisk completed the €10.66 billion acquisition of Catalent, including three production plants to scale up Wegovy production. Despite rivals’ opposition, the deal secures Novo’s market edge. Additionally, the company plans a €1.14 billion investment in a rare-disease drug facility. Boosted by Wegovy sales, Novo reported a 48% revenue increase in Q3 to $2.313 billion. 0 SHARES

Novartis plans to sell Morphosys' business, acquired for €2.7 billion in 2023, affecting 330 employees as it closes two factories by 2025.

Grifols faced a turbulent 2024 with leadership changes, legal battles, and debt refinancing. Accusations by Gotham City Research and a rejected takeover bid from Brookfield added pressure. Despite setbacks, the company focused on restructuring, selling assets, and extending debt maturity to 2030. Grifols now aims to stabilize operations while managing ongoing challenges and market expectations.